Disclaimer: This article is for educational and informational purposes only. Injectable GHK-Cu is a research-use only (RUO) compound with no FDA, ANVISA, or equivalent regulatory approval for human therapeutic use. Consult a licensed healthcare professional before considering any peptide protocol.
What Is GHK-Cu?
GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide first isolated from human plasma albumin in 1973 by Loren Pickart at the University of California, San Francisco. It is found endogenously in plasma, saliva, and urine. Pickart's foundational work documented a decline in circulating GHK-Cu levels with age — from roughly 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 (figures referenced in Pickart et al., BioMed Research International, 2015) — a pattern that seeded interest in its potential role in age-related tissue changes.
The compound's defining biochemical feature is high-affinity binding of copper(II) ions, cofactors essential for collagen cross-linking, lysyl oxidase activity, and superoxide dismutase function. The free tripeptide (GHK) has a molecular weight of approximately 340 Da; the copper(II) complex (GHK-Cu) has a molecular weight of approximately 403 Da. Its size permits dermal penetration in topical formulations and rapid systemic distribution in animal injection models.
Mechanism of Action: What the Research Literature Shows
The most cited mechanistic work comes from Pickart and collaborators. A 2015 review published in BioMed Research International (Pickart, Vasquez-Soltero & Margolina; DOI: 10.1155/2015/648108; PMC4508379) analyzed gene expression datasets and characterized GHK-Cu as a modulator of pathways related to collagen and glycosaminoglycan synthesis, antioxidant defense, and anti-inflammatory signaling. A follow-up 2018 paper in International Journal of Molecular Sciences extended this analysis to aging tissue transcriptomes, identifying modulation of thousands of gene transcripts.
Evidence note: Both papers draw heavily on in silico bioinformatics analysis of public gene expression databases — not controlled human clinical trials. The gene counts cited are derived from computational queries, not from measuring gene expression in treated humans. Readers should weight these findings as hypothesis-generating, not confirmatory.
Evidence by Research Area
Wound Healing and Tissue Remodeling
The strongest body of evidence for GHK-Cu relates to wound healing. Pickart's 2008 review in the Journal of Biomaterials Science, Polymer Edition (DOI: 10.1163/156856208784909435; PMID: 18644225) synthesized data from animal models and early-phase human studies showing that topical GHK-Cu accelerates wound closure, stimulates collagen and glycosaminoglycan production, and promotes angiogenesis in wound beds. This evidence base is for topical application.
Evidence grade for injectable use: Preclinical (animal models) only. No large randomized controlled trials evaluating injectable GHK-Cu in humans have been published in indexed journals as of mid-2026. Any claims of human clinical benefit from injection remain unsupported by controlled trial data.
Skin Remodeling
Several small human trials have assessed topical GHK-Cu formulations for skin aging markers — laxity, fine lines, dermal thickness. Results have generally been positive, but these studies involve fewer than 50 participants each and use topical, not injectable, delivery. Translating topical findings to systemic injection protocols is not scientifically justified without separate pharmacokinetic and efficacy data for the injectable route.
Anti-inflammatory and Cytoprotective Effects
Rodent model data suggest GHK-Cu reduces pro-inflammatory cytokine expression (TNF-α, IL-6) and may attenuate oxidative tissue damage. These findings have not been replicated in published human injection studies. Evidence level: animal/in vitro only.
How Researchers Reconstitute and Administer Injectable GHK-Cu
The following describes procedures documented in research literature and standard RUO supplier protocols. This is not a prescription, clinical recommendation, or instruction for self-administration.
Reconstitution
- GHK-Cu is supplied as a lyophilized (freeze-dried) powder, typically in vials ranging from 50 mg to 200 mg.
- Most research protocols use bacteriostatic water for injection (0.9% benzyl alcohol) as the reconstitution solvent for multi-dose vials; sterile saline is used when single-use administration is planned.
- Solvent is added slowly along the interior vial wall, then the vial is swirled gently — not shaken. Aggressive agitation can degrade peptide conformation.
- Properly reconstituted GHK-Cu forms a clear solution with a characteristic light-blue tint due to copper chelation. Turbidity, precipitate, or color change suggests degradation.
- To convert a target research dose from milligrams or micrograms to the correct injection volume based on your specific reconstitution concentration, use the PeptideMed peptide calculator.
Administration Routes Used in Research
Published animal studies have primarily used subcutaneous (SC) and intraperitoneal (IP) injection. Subcutaneous is the most commonly referenced route in RUO protocols due to reproducible absorption kinetics and technical accessibility in rodent models. Intravenous administration appears in isolated mechanistic experiments. No peer-reviewed consensus exists on preferred routes, dosing frequency, or dose ranges for human administration.
Storage After Reconstitution
| State | Recommended Temperature | Estimated Stability |
|---|---|---|
| Lyophilized powder (sealed) | −20°C | 12–24 months (manufacturer-dependent) |
| Reconstituted solution | 2–8°C (refrigerator) | Up to 30 days |
| Reconstituted at room temperature | Not recommended for storage | Use within hours if unavoidable |
All forms should be protected from direct light. Avoid freeze-thaw cycling after reconstitution, as repeated temperature shifts accelerate peptide degradation.
Regulatory Status
- FDA (USA): GHK-Cu carries no FDA drug approval in any route or indication. Topical GHK-Cu is present in approved cosmetic ingredient listings (INCI: Copper Tripeptide-1); injectable forms have no approval and are classified RUO. Compounding update (April 2026): The FDA removed injectable GHK-Cu from the 503A Category 2 "do not compound" list. This removal does not confer compounding eligibility — a Pharmacy Compounding Advisory Committee (PCAC) review scheduled before February 2027 will determine whether injectable GHK-Cu may be added to the 503A bulk drug substances list. This status is actively evolving; verify the current regulatory position before designing any protocol.
- ANVISA (Brazil): GHK-Cu does not appear in ANVISA's list of approved active pharmaceutical ingredients for parenteral use. Researchers should verify current RDC regulations and magistral compounding rules before any human-use protocol.
- WADA: GHK-Cu does not appear on the 2026 WADA Prohibited List (in force since January 1, 2026). The list is updated annually — always verify the current version at wada-ama.org before any competitive sport application.
Open Questions Before Clinical Translation
The published literature leaves several questions unanswered for injectable GHK-Cu in humans:
- Subcutaneous bioavailability and plasma half-life in humans
- Tissue distribution and potential copper accumulation with repeated dosing
- Dose-response relationships for any claimed outcome
- Long-term safety data (none published)
Any human research protocol would require IRB (or equivalent ethics board) approval and pharmacokinetic characterization before proceeding.
Related Peptides in Tissue Repair Research
GHK-Cu is frequently studied alongside other tissue-repair peptides. Two that appear in overlapping research contexts:
- BPC-157 — a pentadecapeptide derived from gastric juice protein BPC. Extensively studied in rodent models for tendon, muscle, and mucosal repair; evidence base is predominantly animal, with isolated human case reports. Often researched via subcutaneous or oral routes. Anti-doping status: BPC-157 is prohibited under the WADA 2026 Prohibited List (categories S0 — Non-Approved Substances — and S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics) and is banned for competitive athletes at all times, with no Therapeutic Use Exemption pathway available.
- TB-500 (Thymosin Beta-4 synthetic fragment) — studied for angiogenesis promotion and actin-dependent cell migration in wound models. Research interest overlaps with GHK-Cu in skin and connective tissue repair contexts, also at the preclinical stage for systemic administration. Anti-doping status: TB-500, Thymosin Beta-4, and their fragments are prohibited under the WADA 2026 Prohibited List (categories S0 and S2) and are banned for competitive athletes at all times, with no Therapeutic Use Exemption pathway available.